Detection of Novel Gene Mutations Associated with Pyrazinamide Resistance in Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Southern China

References

• Yadon AN, Maharaj K, Adamson JH, et al. A comprehensive characterization of pncA polymorphisms that confer resistance to pyrazinamide. Nat Commun. 2017;8(1):588. doi:10.1038/s41467-017-00721-228928454
   PubMed Web of Science ®Google Scholar
• Whitfield MG, Streicher EM, York T, et al. Association between genotypic and phenotypic pyrazinamide resistance in Mycobacterium tuberculosis. Int J Infect Dis. 2014;21:96. doi:10.1016/j.ijid.2014.03.628
   Web of Science ®Google Scholar
• Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med. 1996;2:662. doi:10.1038/nm0696-6628640557
   PubMed Web of Science ®Google Scholar
• Islam MM, Hameed HMA, Mugweru J, et al. Drug resistance mechanisms and novel drug targets for tuberculosis therapy. J Genet Genomics. 2017;44(1):21–37. doi:10.1016/j.jgg.2016.10.00228117224
   PubMed Web of Science ®Google Scholar
• Ramirez-Busby SM, Rodwell TC, Fink L, et al. A multinational analysis of mutations and heterogeneity in pZase, rpsA, and panD associated with pyrazinamide resistance in M/XDR Mycobacterium tuberculosis. Sci Rep. 2017;7:3790. doi:10.1038/s41598-017-03452-y28630430
   PubMed Web of Science ®Google Scholar
• Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science. 2011;333(6049):1630–1632. doi:10.1126/science.120881321835980
   PubMed Web of Science ®Google Scholar
• Shi W, Chen J, Zhang S, Zhang W, Zhang Y. Identification of novel mutations in LprG (rv1411c), rv0521, rv3630, rv0010c, ppsC, and cyp128 associated with pyrazinoic acid/pyrazinamide resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018;62(7):e00430–18. doi:10.1128/AAC.00430-1829686155
   PubMed Web of Science ®Google Scholar
• Zhang S, Chen J, Shi W, Liu W, Zhang W, Zhang Y. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microb Infect. 2013;2:e34. doi:10.1038/emi.2013.38
   PubMed Web of Science ®Google Scholar
• Njire M, Wang N, Wang B, et al. Pyrazinoic acid inhibits a bifunctional enzyme in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2017;61(7):e00070–17. doi:10.1128/AAC.00070-1728438933
   PubMed Web of Science ®Google Scholar
• Yee M, Gopal P, Dick T. Missense mutations in the unfoldase ClpC1 of the caseinolytic protease complex are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2017;61:2.
   Web of Science ®Google Scholar
• Barco P, Cardoso RF, Hirata RDC, et al. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J Antimicrob Chemother. 2006;58(5):930–935. doi:10.1093/jac/dkl36316971417
   PubMed Web of Science ®Google Scholar
• Tan Y, Hu Z, Zhang T, et al. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China. J Clin Microbiol. 2014;52(1):291–297. doi:10.1128/JCM.01903-1324131688
   PubMed Web of Science ®Google Scholar
• Liu W, Chen J, Shen Y, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China. Clin Microbiol Infect. 2018;24(9):1016.e1-e5. doi:10.1016/j.cmi.2017.12.012
   Web of Science ®Google Scholar
• Li D, Hu Y. pncA mutations in Mycobacterium tuberculosis is a strong predictor of poor treatment outcome in the therapy of multidrug resistant tuberculosis. Int J Infect Dis. 2016;45:92–93. doi:10.1016/j.ijid.2016.02.24626952389
   PubMed Web of Science ®Google Scholar
• Pang Y, Dong H, Tan Y, et al. Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China. Sci Rep. 2016;6:25330. doi:10.1038/srep2533027149911
   PubMed Web of Science ®Google Scholar
• World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. 2018.
   Google Scholar
• Mustafa S, Javed H, Hashmi J, Jamil N, Tahir Z, Akhtar AM. Emergence of mixed infection of Beijing/Non-Beijing strains among multi-drug resistant Mycobacterium tuberculosis in Pakistan. 3 Biotech. 2016;6(1):108. doi:10.1007/s13205-016-0423-9
   Google Scholar
• Ando H, Mitarai S, Kondo Y, et al. Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan. Clin Microbiol Infect. 2010;16(8):1164–1168. doi:10.1111/j.1469-0691.2009.03078.x19832709
   PubMed Web of Science ®Google Scholar
• Jonmalung J, Prammananan T, Leechawengwongs M, Chaiprasert A. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol. 2010;10(1):223. doi:10.1186/1471-2180-10-22320727143
   PubMed Web of Science ®Google Scholar
• Mphahlele M, Syre H, Valvatne H, et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol. 2008;46(10):3459–3464. doi:10.1128/JCM.00973-0818753350
   PubMed Web of Science ®Google Scholar
• Islam MM, Tan Y, Hameed HMA, et al. Detection of novel mutations associated with independent and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates. Clin Microbiol Infect. 2019;25(8):1041.e1-e7. doi:10.1016/j.cmi.2018.12.008
   Web of Science ®Google Scholar
• Sun Z, Chao Y, Zhang X, et al. Characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates in China. J Clin Microbiol. 2008;46(12):4075–4077. doi:10.1128/JCM.00822-0818945837
   PubMed Web of Science ®Google Scholar
• Xia Q, Zhao L-L, Li F, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China. Antimicrob Agents Chemother. 2015;59(3):1690–1695. doi:10.1128/AAC.04541-1425583712
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, von Groote-bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 2012;380(9846):986–993. doi:10.1016/S0140-6736(12)61080-022828481
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med. 2015;191(8):943–953. doi:10.1164/rccm.201410-1801OC25622149
   PubMed Web of Science ®Google Scholar
• Bhuju S, Fonseca L, Marsico AG, et al. Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene. Infect Genet Evol. 2013;19:1–6. doi:10.1016/j.meegid.2013.06.00823770140
   PubMed Web of Science ®Google Scholar
• Hameed HMA, Islam MM, Chhotaray C, et al. Molecular targets related drug resistance mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis strains. Front Cell Infect Microbiol. 2018;2018(8):114. doi:10.3389/fcimb.2018.00114
   Web of Science ®Google Scholar
• Akhmetova A, Kozhamkulov U, Bismilda V, et al. Mutations in the pncA and rpsA genes among 77 Mycobacterium tuberculosis isolates in Kazakhstan. Int J Tuberc Lung Dis. 2015;19(2):179–184. doi:10.5588/ijtld.14.030525574916
   PubMed Web of Science ®Google Scholar
• Gu Y, Yu X, Jiang G, et al. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations. Diagn Microbiol Infect Dis. 2016;84(3):207–211. doi:10.1016/j.diagmicrobio.2015.10.01726775806
   PubMed Web of Science ®Google Scholar
• Shi W, Chen J, Feng J, et al. Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis. Emerg Microb Infect. 2014;3(8):e58. doi:10.1038/emi.2014.61
   Web of Science ®Google Scholar
• Gopal P, Yee M, Sarathy J, et al. Pyrazinamide resistance is caused by two distinct mechanisms: prevention of coenzyme a depletion and loss of virulence factor synthesis. ACS Infect Dis. 2016;2(9):616–626. doi:10.1021/acsinfecdis.6b0007027759369
   PubMed Web of Science ®Google Scholar
• Raju RM, Jedrychowski MP, Wei J-R, et al. Post-translational regulation via Clp protease is critical for survival of Mycobacterium tuberculosis. PLoS Pathog. 2014;10(3):e1003994. doi:10.1371/journal.ppat.100399424603869
   PubMed Web of Science ®Google Scholar
• Baddam R, Kumar N, Wieler LH, et al. Analysis of mutations in pncA reveals non-overlapping patterns among various lineages of Mycobacterium tuberculosis. Sci Rep. 2018;8(1):4628. doi:10.1038/s41598-018-22883-929545614
   PubMed Web of Science ®Google Scholar
• Xu P, Wu J, Yang C, et al. Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China. Tuberculosis (Edinb). 2016;98:56–61. doi:10.1016/j.tube.2016.02.00827156619
   PubMed Web of Science ®Google Scholar
• Kim H, Kwak H, Lee J, et al. Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea. Int J Tuberc Lung Dis. 2012;16(1):98–103. doi:10.5588/ijtld.10.073922236853
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Morlock GP, Sikes RD, et al. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2011;55(5):2032–2041. doi:10.1128/AAC.01550-1021300839
   PubMed Web of Science ®Google Scholar
• Feuerriegel S, Oberhauser B, George AG, et al. Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting. BMC Microbiol. 2012;12(1):90. doi:10.1186/1471-2180-12-9022646308
   PubMed Web of Science ®Google Scholar
• Simons S, van der Laan T, Mulder A, et al. Rapid diagnosis of pyrazinamide‐resistant multidrug‐resistant tuberculosis using a molecular‐based diagnostic algorithm. Clin Microbiol Infect. 2014;20(10):1015–1020. doi:10.1111/1469-0691.1269624890253
   PubMed Web of Science ®Google Scholar
• Cui Z, Wang J, Lu J, Huang X, Zheng R, Hu Z. Evaluation of methods for testing the susceptibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide. J Clin Microbiol. 2013;51(5):1374–1380. doi:10.1128/JCM.03197-1223390285
   PubMed Web of Science ®Google Scholar
• Pang Y, Zhu D, Zheng H, et al. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infect Dis. 2017;17(1):711. doi:10.1186/s12879-017-2761-629110640
   PubMed Web of Science ®Google Scholar